Ownership & Investor Warrants
Information on the share and investor warrants
Exchange and ticker
As per 10 June, 2020, the Company’s share capital is 8,011,647.85 of nominal DKK 0.05 each, and the number of shares are 160.232.957 DKK.
Share capital is set in Danish kroner (DKK). All shares give equal rights to the company’s assets, profits and any possibly liquidation surplus.
Identification code (ISIN)
The company is listed on NASDAQ OMX Nasdaq First North Growth Market, ISIN code (identification code for the company’s shares) is ISIN DK0060732477.
As of 15 May, 2020, the company had 8,091 shareholders.
As of 15 May, 2020, the shareholder base were as follows:
|Shareholder name||Number of shares||Percentage|
|Sass & Larsen||8,690,524||6.5 %|
|UBS Switzerland AG||8,235,426||6.2 %|
Investor warrants series TO 2
The investor warrants of series “Oncology Venture TO 2” is traded on Nasdaq First North Growth Market under the ticker “OV TO 2“.
The total number of warrants within the series 50,341,080.
Terms and conditions
One (1) investor warrant received when participating in the rights issue in Oncology Venture at the end of 2019 gives the right to subscribe for one (1) new share in Oncology Venture A/S at an issue price of 6.00 SEK.
Investors in the Rights Issue will have the possibility to exercise their warrants in five two-week windows during the 24-months period during which the warrants may be exercised.
These periods are:
- April 1, 2020 – April 15, 2020
- September 1, 2020 – September 15, 2020
- February 1, 2021 – February 15, 2021
- May 1, 2021 – May 15, 2021
- September 1, 2021 – September 15, 2021